Bucladesine: Difference between revisions
No edit summary |
No edit summary |
||
Line 23: | Line 23: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Line 38: | Line 39: | ||
[[Category:Phosphodiesterase inhibitors]] | [[Category:Phosphodiesterase inhibitors]] | ||
[[Category:Cardiovascular Drugs]] | [[Category:Cardiovascular Drugs]] | ||
[[Category: | [[Category:Drug]] | ||
Latest revision as of 20:35, 24 July 2014
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C18H23N5NaO8P |
Molar mass | 491.368 g/mol |
WikiDoc Resources for Bucladesine |
Articles |
---|
Most recent articles on Bucladesine Most cited articles on Bucladesine |
Media |
Powerpoint slides on Bucladesine |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Bucladesine at Clinical Trials.gov Clinical Trials on Bucladesine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Bucladesine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Bucladesine Discussion groups on Bucladesine Patient Handouts on Bucladesine Directions to Hospitals Treating Bucladesine Risk calculators and risk factors for Bucladesine
|
Healthcare Provider Resources |
Causes & Risk Factors for Bucladesine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Bucladesine is a cyclic nucleotide derivative which mimics the action of endogenous cAMP and is a phosphodiesterase inhibitor.
Bucladesine is a cell permeable cAMP analog. The compound is used in a wide variety of research applications because it mimics cAMP and can induce normal physiological responses when added to cells in experimental conditions. cAMP is only able to elicit minimal responses in these situations.
The neurite outgrowth instigated by bucladesine in cell cultures has been shown to be enhanced by nardosinone.
Template:Phosphodiesterase inhibitors Template:Cardiac stimulants excluding cardiac glycosides
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Phosphodiesterase inhibitors
- Cardiovascular Drugs
- Drug